Which medications in the drug class Anti-CD20 Monoclonal Antibodies are used in the treatment of Polymyositis?

Updated: Jan 05, 2021
  • Author: Mythili Seetharaman, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Anti-CD20 Monoclonal Antibodies

Clinical trials with rituximab have shown encouraging results in patients who are refractory to first-line treatment.

Rituximab (Rituxan)

(Off-label) Rituximab is a humanized monoclonal antibody that binds to CD20 antigen, thereby inducing complement- or antibody-mediated cytolysis. Clinical trials in refractory polymyositis have shown improvement in patients who have failed corticosteroids and other immunosuppressive agents.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!